Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

1 Day ROG -1.02% DJIA 0.59% S&P 500 0.38% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

The Revised National Informal Economic Policy (NIEP) 2024-2034 is designed to support and empower Papua New Guineans involved in the informal sector, according to a government official.